IL17A and psoriasis: A clinical study has demonstrated that psoriasis patients treated with secukinumab (an IL-17A antibody) for 12 weeks exhibited a reversal of plaque histopathology, along with a significant reduction in the levels of upstream cytokines IL-23 and IL-17A (3).